Published in J Bioenerg Biomembr on December 01, 2009
The role of oxidative stress in Parkinson's disease. J Parkinsons Dis (2013) 1.86
Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci U S A (2015) 1.69
Increase in blood-brain barrier permeability, oxidative stress, and activated microglia in a rat model of blast-induced traumatic brain injury. J Neurosci Res (2010) 1.45
Axon degeneration in Parkinson's disease. Exp Neurol (2012) 1.40
The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons. J Neurosci (2011) 1.31
Parkin-mediated selective mitochondrial autophagy, mitophagy: Parkin purges damaged organelles from the vital mitochondrial network. FEBS Lett (2010) 1.24
Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. Oxid Med Cell Longev (2015) 1.13
Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs. Free Radic Biol Med (2013) 1.09
Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim Biophys Acta (2013) 1.04
Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility. Front Neurosci (2013) 0.99
Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacol Ther (2014) 0.94
Glutathione Peroxidase 4 is associated with Neuromelanin in Substantia Nigra and Dystrophic Axons in Putamen of Parkinson's brain. Mol Neurodegener (2011) 0.93
The role of thyroid hormones as inductors of oxidative stress and neurodegeneration. Oxid Med Cell Longev (2013) 0.91
WldS but not Nmnat1 protects dopaminergic neurites from MPP+ neurotoxicity. Mol Neurodegener (2012) 0.89
Thiol-redox signaling, dopaminergic cell death, and Parkinson's disease. Antioxid Redox Signal (2012) 0.88
Long-term effects of ionising radiation on the brain: cause for concern? Radiat Environ Biophys (2012) 0.86
Impaired metabolic reactivity to oxidative stress in early psychosis patients. Schizophr Bull (2014) 0.85
Human SOD2 modification by dopamine quinones affects enzymatic activity by promoting its aggregation: possible implications for Parkinson's disease. PLoS One (2012) 0.85
Associations of Ozone and PM2.5 Concentrations With Parkinson's Disease Among Participants in the Agricultural Health Study. J Occup Environ Med (2015) 0.82
Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons. Cell Death Dis (2015) 0.81
Mitochondria-Targeted Protective Compounds in Parkinson's and Alzheimer's Diseases. Oxid Med Cell Longev (2015) 0.80
Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration. Parkinsonism Relat Disord (2015) 0.79
Neurotransmitter CART as a New Therapeutic Candidate for Parkinson's Disease. Pharmaceuticals (Basel) (2013) 0.76
Dopamine induces the accumulation of insoluble prion protein and affects autophagic flux. Front Cell Neurosci (2015) 0.76
Mic60/mitofilin overexpression alters mitochondrial dynamics and attenuates vulnerability of dopaminergic cells to dopamine and rotenone. Neurobiol Dis (2016) 0.76
Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies. Parkinsonism Relat Disord (2016) 0.75
Redox Imbalance and Viral Infections in Neurodegenerative Diseases. Oxid Med Cell Longev (2016) 0.75
Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease. Drug Des Devel Ther (2017) 0.75
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease. Mol Neurodegener (2016) 0.75
Mitochondrial matters in Parkinson disease: introduction. J Bioenerg Biomembr (2009) 0.75
Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol (2008) 17.81
Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci (2000) 10.62
Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet (2009) 3.56
Dopamine covalently modifies and functionally inactivates parkin. Nat Med (2005) 3.43
Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest (2008) 3.23
The mitochondrial inner membrane protein mitofilin controls cristae morphology. Mol Biol Cell (2005) 2.53
Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci (2007) 2.39
Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci (2007) 2.28
Structural and functional link between the mitochondrial network and the endoplasmic reticulum. Int J Biochem Cell Biol (2009) 2.20
A highly reproducible rotenone model of Parkinson's disease. Neurobiol Dis (2009) 1.92
Dopamine neurons release transmitter via a flickering fusion pore. Nat Neurosci (2004) 1.87
Biomedicine. Parkinson's--divergent causes, convergent mechanisms. Science (2004) 1.87
Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis (2006) 1.83
Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol (1978) 1.79
Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci U S A (1996) 1.75
Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem (1999) 1.74
Cytotoxic and genotoxic potential of dopamine. J Neurosci Res (1999) 1.70
Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp Neurol (2009) 1.68
Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann N Y Acad Sci (2000) 1.67
Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci (2004) 1.63
The mitochondrial inner membrane protein mitofilin exists as a complex with SAM50, metaxins 1 and 2, coiled-coil-helix coiled-coil-helix domain-containing protein 3 and 6 and DnaJC11. FEBS Lett (2007) 1.53
Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci (2003) 1.51
Glutathione--a review on its role and significance in Parkinson's disease. FASEB J (2009) 1.50
Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci (2008) 1.43
Nitric oxide induces coupling of mitochondrial signalling with the endoplasmic reticulum stress response. Nat Cell Biol (2004) 1.38
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta (2008) 1.35
Mendelian forms of Parkinson's disease. Biochim Biophys Acta (2009) 1.33
Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem (1995) 1.31
Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem (1998) 1.24
Oxidative stress-triggered unfolded protein response is upstream of intrinsic cell death evoked by parkinsonian mimetics. J Neurochem (2006) 1.23
Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology. Exp Neurol (2009) 1.19
Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol Dis (2009) 1.11
Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci (2008) 1.10
Quantitative biochemical and ultrastructural comparison of mitochondrial permeability transition in isolated brain and liver mitochondria: evidence for reduced sensitivity of brain mitochondria. Exp Neurol (2000) 1.05
Identification of catechol-protein conjugates in neostriatal slices incubated with [3H]dopamine: impact of ascorbic acid and glutathione. J Neurochem (1994) 1.05
Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience (2000) 0.99
Changes in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamine. J Neurochem (2008) 0.98
Proteomic analysis of rat brain mitochondria following exposure to dopamine quinone: implications for Parkinson disease. Neurobiol Dis (2007) 0.95